Pelthos Therapeutics Inc. (PTHS) stock
PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.84−0.31 (-4.34%)
Close on Nov 17, 2026Market cap $26.19MP/E –Yield –
Pelthos Therapeutics cash
Cash and short-term investments held at the end of each period.
Pelthos Therapeutics's cash was $24.19M at Jun 30, 2026. For fiscal 2025 it was $17.97M, up 3403.5% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.97M | +3403.5% |
| FY2024 | Dec 31, 2024 | $513.00K | +434.4% |
| FY2023 | Dec 31, 2023 | $96.00K | +74.3% |
| FY2022 | Dec 31, 2022 | $55.07K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.19M | +40903.4% |
| Q1 FY2026 | Mar 31, 2026 | $31.98M | +24309.2% |
| Q4 FY2025 | Dec 31, 2025 | $17.97M | +3403.5% |
| Q3 FY2025 | Sep 30, 2025 | $14.20M | +1031.7% |
| Q2 FY2025 | Jun 30, 2025 | $59.00K | -97.5% |
| Q1 FY2025 | Mar 31, 2025 | $131.00K | -96.5% |
| Q4 FY2024 | Dec 31, 2024 | $513.00K | +434.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.26M | +5407.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.41M | +2836.9% |
| Q1 FY2024 | Mar 31, 2024 | $3.77M | +7656.4% |
| Q4 FY2023 | Dec 31, 2023 | $96.00K | +74.3% |
| Q3 FY2023 | Sep 30, 2023 | $22.79K | – |
| Q2 FY2023 | Jun 30, 2023 | $81.89K | – |
| Q1 FY2023 | Mar 31, 2023 | $48.61K | – |
| Q4 FY2022 | Dec 31, 2022 | $55.07K | – |
See a number that looks wrong?